It may be possible that participants in Cluster 4 had the most severe cognitive impairment and the highest levels of CSF p-tau at baseline already, and thus the potential for CSF p-tau to further increase was limited, particularly at the later stages of the disease. This evidence concerns the gene MAPT and Cognitive impairment.